QT
NGM

Quantbot Technologies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Quantbot Technologies’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,300
Closed -$4.55K – 2064
2023
Q4 		$4.55K Hold
5,300
– – ﹤0.01% 1495
2023
Q3 		$5.67K Sell
5,300
-200
-4% -$414 ﹤0.01% 1446
2023
Q2 		$14.2K Buy
5,500
+1,524
+38% +$5.44K ﹤0.01% 1440
2023
Q1 		$16.2K Sell
3,976
-5,342
-57% -$24.7K ﹤0.01% 1372
2022
Q4 		$46.8K Buy
9,318
+8,790
+1,665% +$55.1K ﹤0.01% 1318
2022
Q3 		$6K Sell
528
-5,404
-91% -$81.8K ﹤0.01% 1470
2022
Q2 		$76K Buy
5,932
+4,505
+316% +$62.4K 0.01% 1216
2022
Q1 		$21K Sell
1,427
-3,773
-73% -$58.8K ﹤0.01% 1355
2021
Q4 		$92K Buy
5,200
+3,800
+271% +$72.9K 0.01% 895
2021
Q3 		$29K Buy
+1,400
New +$30.8K ﹤0.01% 1208
2021
Q1 		– Sell
-200
Closed -$6K – 1844
2020
Q4 		$6K Buy
+200
New +$4.38K ﹤0.01% 1153
2020
Q3 		– Sell
-82
Closed -$1K – 1720
2020
Q2 		$1K Buy
+82
New +$1.57K ﹤0.01% 1076

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Quantbot Technologies's NGM Position: Q1 2024 in Review

Quantbot Technologies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 5,300 shares — an estimated $4.55K sold.

Quantbot Technologies first reported a position in NGM in Q2 2020 and held it in 12 quarters. The position peaked at $92K in Q4 2021. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Quantbot Technologies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Quantbot Technologies sold 5,300 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $4.55K.
  • Quantbot Technologies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Quantbot Technologies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $92K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Quantbot Technologies's 13F filing for Q1 2024, filed 6 May 2024.